Therapeutic modulation of the TWEAK/Fn14 pathway has been successful in experimental models of AKI, kidney fibrosis, lipid-induced kidney injury, proteinuria-induced kidney injury, and immune-mediated glomerular injury, including lupus nephritis. This evidence concerns the gene TNFSF12 and lupus nephritis.